Sacubitril–valsartan Elderly Multimorbidity Six-minute walking test NYHA MAGGIC score
Wiley Open Access
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Rodil-Fraile, R. (Raquel); Malafarina, V. (Vincenzo); Tiberio-López, T. (Tiberio). "Sacubitril-valsartan in heart failure and multimorbidity patients". Esc hear failure. 5 (5), 2018, 956 - 959
Aims The poor control of symptoms in patients with advanced heart failure with reduced ejection function (HFrEF) can limit
the functionality of patients. Sacubitril–valsartan, compared with enalapril, has been shown to reduce mortality and hospitalization, and nowadays, there is still little evidence about the improvement on functionality. The aim of our study is to analyse
the improvement of the functional class and the 6 min walking test (6MWT) in patients with multiple pathologies and
advanced heart failure.
Methods and results From September 2016 to March 2018, 65 multimorbidity patients with severe symptomatic HFrEF
were initiated to receive sacubitril–valsartan. Mean age was 78.6 ± 7.4 years, and 68% were male. The Charlson
co-morbidity index was 8 points. Seventy-four per cent had New York Heart Association (NYHA) Functional Class IV. After
the treatment, patients were able to achieve 55.68 m or more on 6MWT, and 91% presented an improvement in the NYHA
Conclusions Sacubitril–valsartan relieves symptoms and improves functional class prognostic risk of patients with advanced
HFrEF and co-morbidity